Alkermes Plc news

   Watch this stock
Showing stories 1 - 10 of about 87   

Articles published

ALKS 46.77 -0.29 (-0.62%)
price chart
Alkermes plc: Alkermes to Host Conference Call to Discuss First Quarter 2014 ...
DUBLIN--(BUSINESS WIRE)--Apr. 23, 2014-- Alkermes plc (NASDAQ: ALKS) will host a conference call at 8:30 a.m. EDT (1:30 p.m.
Alkermes to Host Conference Call to Discuss First Quarter 2014 Financial Results  Wall Street Journal
Related articles »  
Alkermes Plc Rating Lowered to Neutral at Zacks (ALKS)
Alkermes Plc logo Alkermes Plc (NASDAQ:ALKS) was downgraded by Zacks from an �outperform� rating to a �neutral� rating in a report issued on Wednesday, StockRatingsNetwork.
Related articles »  
Alkermes Plc (ALKS) Is Rising On Phase 3 Study Results
(RTTNews.com) - Alkermes plc ( ALKS ) announced positive topline results from a phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia Tuesday morning.
Alkermes to seek schizophrenia drug approval after trial success  Chicago Tribune (blog)
Alkermes Announces Positive Topline Results From Pivotal Phase 3 Study of ...  MarketWatch
Related articles »  
Alkermes Plc's �Outperform� Rating Reaffirmed at Leerink Swann (ALKS)
Alkermes Plc logo Leerink Swann reiterated their outperform rating on shares of Alkermes Plc (NASDAQ:ALKS) in a research report sent to investors on Tuesday morning, Analyst Ratings Network reports.
Alkermes Plc Given New $35.00 Price Target at MKM Partners (ALKS)  Ticker Report
Alkermes Plc Rating Increased to Buy at Mizuho (ALKS)  Mideast Time
Related articles »  
Alkermes Plc Downgraded by Zacks to Neutral (ALKS)
Alkermes Plc logo Alkermes Plc (NASDAQ:ALKS) was downgraded by Zacks from an �outperform� rating to a �neutral� rating in a research note issued to investors on Wednesday, Analyst Ratings News reports.
Watch List �Alkermes Plc (NASDAQ:ALKS), Hologic, Inc (NASDAQ:HOLX ...
Birmingham, West Midlands - (TechSonian) - 21 April 2014 - Alkermes Plc (NASDAQ:ALKS) declared the origination of the pivotal clinical development program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action ...
Alkermes Plc Upgraded to �Buy� at Mizuho (ALKS)
Alkermes Plc logo Alkermes Plc (NASDAQ:ALKS) was upgraded by equities research analysts at Mizuho from a �neutral� rating to a �buy� rating in a research note issued to investors on Thursday, TheFlyOnTheWall.
Notable Movers - Alkermes Plc (NASDAQ:ALKS), Jazz Pharmaceuticals plc ...  Techsonian (press release)
Related articles »  
Alkermes Plc Stock Rating Lowered by Zacks (ALKS)
Alkermes Plc logo Zacks downgraded shares of Alkermes Plc (NASDAQ:ALKS) from an outperform rating to a neutral rating in a report issued on Wednesday, American Banking & Market News reports.
Related articles »  
Stocks in the Spotlight: Alkermes Plc (ALKS), Qunar Cayman Islands Ltd (QUNR ...
Alkermes Plc (NASDAQ:ALKS) shares advanced over 7 percent in the current trading session after the biopharmaceutical company announced that its experimental drug for the treatment of schizophrenia's symptoms met the main objective of lowering the ...
Insider Selling: Alkermes Plc CFO Sells 7000 Shares of Stock (ALKS)
Alkermes Plc logo Alkermes Plc (NASDAQ:ALKS) CFO James M. Frates sold 7,000 shares of Alkermes Plc stock in a transaction that occurred on Wednesday, April 9th.
Alkermes Plc Upgraded to "Buy" by Mizuho (ALKS)  Zolmax
Related articles »